BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected



Last update:

LONDON–(BUSINESS WIRE)–BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI.

  • Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca
  • First target to be selected from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of Target Identification

BenevolentAI’s strategic collaboration with AstraZeneca began in 2019, and originally focused on discovering potential new treatments for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD). The collaboration was expanded in January 2022 to two new disease areas, Heart Failure and Systemic Lupus Erythematosus (SLE), demonstrating how the Benevolent Platform™ can be applied across multiple therapeutic areas.

The innovative collaboration structure sees scientists and technologists from the two companies work side-by-side, combining BenevolentAI’s AI-driven drug discovery platform and biomedical knowledge with AstraZeneca’s scientific and disease specific expertise, leading to novel and robust Target Identification. Both the initial and extended collaboration were agreed on similar terms with upfront payments on signing, research funding alongside discovery, development and commercial milestones. Additionally, the Company will receive tiered royalties on net sales of any commercialised products.

Heart Failure is a complex syndrome which occurs when the heart cannot pump enough blood around the body. It is often complicated by multiple interrelated diseases, so requires a deep understanding of the potential disease drivers in individual patients. Current heart failure treatments follow a “one-size-fits-all” approach. However, due to the wide range of mechanisms by which heart failure can occur, there remains an unmet need for new therapies as up to 50% of patients die within five years of diagnosis.

Dr Anne Phelan, Chief Scientific Officer of BenevolentAI, said:

“I am delighted that AstraZeneca has selected one of the novel Heart Failure targets that we have been jointly working on to enter its portfolio. Heart Failure is a therapeutic area where there is significant medical need but, due to the size of the market, requires a team effort and significant momentum, so we are delighted to be working with AstraZeneca in this important field of medicine.”

Regina Fritsche Danielson, SVP and Head of Research and Early Development, Cardiovascular, Renal and Metabolism, at AstraZeneca said:

“Our ongoing collaboration with BenevolentAI has been instrumental in uncovering new insights into complex diseases such as CKD and Heart Failure. This shared expertise, combined with the power of AI, has the potential to identify the right therapeutic targets for patients with heart failure and help deliver the next generation of innovative therapies.”

- A message from our partner -

About BenevolentAI

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platform™ that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company’s business model presents multiple routes for value creation, including discovery collaborations with pharma companies like AstraZeneca and Merck and advancing in-house pipelines to inflection points. Headquartered in London, with wet labs in Cambridge (UK), BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Category: non-regulatory


Catherine Isted – Chief Financial Officer

[email protected]
T: +44(0) 203 781 9360

James Osborn

[email protected]
T: +44(0) 203 781 9360

FTI Consulting:
Ben Atwell/Simon Conway/Victoria Foster Mitchell

[email protected]
T: +44 203 727 1000


Follow us:

Business Wire

Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Public relations, investor relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX network. Business Wire’s global newsrooms are available to meet the needs of communications professionals and news media worldwide.

Share to...